共 325 条
[1]
Gradishar WJ(2009)Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer J Clin Oncol 27 3611-3619
[2]
Krasnojon D(2006)Albumin-bound Paclitaxel: in metastatic breast cancer Drugs 66 941-948
[3]
Cheporov S(2011)Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Lancet 377 914-923
[4]
Makhson AN(2010)Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer Clin Breast Cancer 10 160-163
[5]
Manikhas GM(2007)Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666-2676
[6]
Clawson A(2010)Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 3239-3247
[7]
Bhar P(2011)RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 1252-1260
[8]
Robinson DM(2010)Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer J Clin Oncol 28 4594-4600
[9]
Keating GM(2012)Combination anastrozole and fulvestrant in metastatic breast cancer N Engl J Med 367 435-444
[10]
Cortes J(2010)CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer Clin Breast Cancer 10 489-491